NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

SCH708980 With and Without AmBisome for Visceral Leishmaniasis

Phase 1

Withdrawn

Conditions: Leishmaniasis
Effects of Immunotherapy

Interventions: Drug: SCH708980 Anti-IL-10 monoclonal
Drug: AmBisome

First Posted Date: 2011-09-20

Last Posted Date: 2013-08-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT01437020

Locations: 🇮🇳
Kala-Azar Medical Research Center (KAMRC), Rambag Road, Muzaffarpur, India
🇮🇳
Banaras Hindu University, Varanasi, India

Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation

Phase 2

Terminated

Conditions: Kidney Transplantation
Renal Transplantation

Interventions: Drug: Alemtuzumab
Drug: MMF
Biological: Basiliximab
Biological: Belatacept
Drug: Short-term Tac
Drug: tacrolimus
Drug: methylprednisolone

First Posted Date: 2011-09-19

Last Posted Date: 2017-09-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 19

Registration Number: NCT01436305

Locations: 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

Staged Phase I/II Hepatitis C Prophylactic Vaccine

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Biological: AdCh3NSmut1
Other: Placebo
Biological: MVA-NSmut

First Posted Date: 2011-09-19

Last Posted Date: 2019-11-19

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 548

Registration Number: NCT01436357

Locations: 🇺🇸
University of California San Francisco - Tenderloin Clinical Research Center, San Francisco, California, United States
🇺🇸
Johns Hopkins School of Public Health - Wood Clinic, Baltimore, Maryland, United States
🇺🇸
UCSF Community Research Center, San Francisco, California, United States

and more 2 locations

Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine

Phase 1

Completed

Conditions: Dengue

Interventions: Biological: TetraVax-DV Vaccine - Admixture TV003
Biological: Placebo
Biological: TetraVax-DV Vaccine - Admixture TV005

First Posted Date: 2011-09-19

Last Posted Date: 2015-08-20

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 112

Registration Number: NCT01436422

Locations: 🇺🇸
Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland, United States
🇺🇸
Fletcher Allen Health Care (FAHC), General Clinical Research Center (GCRC), Burlington, Vermont, United States
🇺🇸
University of Vermont Vaccine Testing Center, Burlington, Vermont, United States

TIV and High Dose TIV in Subjects With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Influenza

Interventions: Biological: Trivalent inactivated influenza vaccine

First Posted Date: 2011-09-19

Last Posted Date: 2014-12-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 102

Registration Number: NCT01436370

Locations: 🇺🇸
University of Iowa - Vaccine Research & Education Unit, Iowa City, Iowa, United States

Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel(Registered Trademark)

Phase 1

Completed

Conditions: Malaria

Interventions: Biological: Pfs25-EPA/Alhydrogel

First Posted Date: 2011-09-14

Last Posted Date: 2014-02-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 30

Registration Number: NCT01434381

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: Inhaled Corticosteroid Boost Therapy (ICS)
Biological: Omalizumab
Biological: Placebo omalizumab
Biological: Placebo fluticasone

First Posted Date: 2011-09-08

Last Posted Date: 2017-05-30

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 478

Registration Number: NCT01430403

Locations: 🇺🇸
Children's Memorial Hospital - Department of Allergy, Chicago, Illinois, United States
🇺🇸
Cincinnati Children's Hospital, Cincinnati, Ohio, United States
🇺🇸
National Jewish Health, Denver, Colorado, United States

and more 5 locations

Interferon Responses in Eczema Herpeticum

Completed

Conditions: Eczema Herpeticum
Atopic Dermatitis
Herpes Simplex Infections
Eczema Vaccinatum

First Posted Date: 2011-09-07

Last Posted Date: 2017-04-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 84

Registration Number: NCT01429311

Locations: 🇺🇸
National Jewish Health, Denver, Colorado, United States

Gene Expression in Liver Allograft Rejection and Recurrent Hepatitis C

Completed

Conditions: Liver Transplantation

First Posted Date: 2011-09-05

Last Posted Date: 2023-03-22

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 275

Registration Number: NCT01428700

Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: Sub C gp140 Vaccine
Other: Sodium chloride
Biological: MF59C.1 Adjuvant

First Posted Date: 2011-08-26

Last Posted Date: 2021-10-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 27

Registration Number: NCT01423825

Locations: 🇺🇸
Fenway Health (FH) CRS, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston, Massachusetts, United States
🇿🇦
Soweto HVTN CRS, Johannesburg, Gauteng, South Africa

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy